Bulletin from the annual general meeting in EQL Pharma AB on 20 August 2026
Regulatory
Today, on 20 August 2026, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
Welcome to EQL Pharma's Investor Pages!
We strive to have an open and proactive dialogue with our shareholders.
Read MoreQ1 2026/2027 Investor Call
Listen to CEO Axel Schörling present EQL Pharma's latest report.
Q1 2026/2027 Investor CallPresentation Q1 2016/2027 Investor CallPress Releases
Memprex© (methenamine hippurate) license signed with partner for Hungary
EQL's key product Memprex© has now been licensed for sale in Hungary with Pharmacenter, a leading local pharmaceutical company specialising in orphan drugs, oncology, urology and hospital products ...
Interim Report April - June 2026
Regulatory
EQL is going through a challenging period, with supply disruptions and technically more complex products in the launch phase, which has caused delays
EQL Pharma in Short
EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.
Read more about usFinancial Calendar
05May2027
Year End Report Q4
04Feb2027
Interim Report Q3
05Nov2026
Interim Report Q2